🇺🇸 FDA
Pipeline program

CITY

APHP240605

Phase 1 other active

Quick answer

CITY for Cutaneous T-cell lymphomas (CTCL) is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Cutaneous T-cell lymphomas (CTCL)
Phase
Phase 1
Modality
other
Status
active

Clinical trials